Company / Free Cash Flow
Aligos Therapeutics, Inc. Free Cash Flow History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$80.9M
FY2024
5-year range
-$116.6M / -$76.3M
FY2020-FY2024
Trend
-0.7%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -$117M to -$81M over the past 2 years.
Based on SEC 10-K filings.
-$81M in FY2024.
Improved from -$117M to -$81M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, free cash flow decreased 0.7% year-over-year.
- Peak free cash flow was recorded in FY2020.
- Lowest free cash flow in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | -$80.9M | -0.7% |
| FY2023 | -$80.3M | +31.1% |
| FY2022 | -$116.6M | -52.7% |
| FY2021 | -$76.3M | -54.0% |
| FY2020 | -$49.6M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026